Skip to main content
Immunotech Biopharm Ltd logo

Immunotech Biopharm Ltd — Investor Relations & Filings

Ticker · 6978 ISIN · KYG4721A1004 HKEX Manufacturing
Open in API
Filings indexed 256 across all filing types
Latest filing 2024-04-29 AGM Information
Country HK Hong Kong
Listing HKEX 6978

About Immunotech Biopharm Ltd

http://www.eaal.net

Immunotech Biopharm Ltd is a biopharmaceutical company specializing in the research, development, manufacturing, and commercialization of cellular immunotherapy products. The company focuses primarily on T cell immunotherapy, applying principles of immunology, cell biology, and genetics combined with advanced technology to develop treatments for malignant tumors and other major diseases. Founded in 2006, it is recognized as a pioneer in the domestic development of cellular immunotherapy products. It maintains a commitment to building systematic R&D platforms and GMP-compliant manufacturing facilities for individualized cell products.

Recent filings

Filing Released Lang Actions
NOTICE OF ANNUAL GENERAL MEETING
AGM Information Classification · 100% confidence The document is a formal notice announcing the Annual General Meeting (AGM) of Immunotech Biopharm Ltd. It includes details about the meeting date, location, agenda items such as adoption of audited financial statements, re-election of directors, appointment of auditors, and approval of mandates related to share issuance and repurchase. The document is titled 'NOTICE OF ANNUAL GENERAL MEETING' and does not contain the actual financial statements or detailed reports but rather the notice to shareholders about the meeting and resolutions to be considered. This fits the definition of AGM Information (AGM-R), which covers presentations and materials shared during the AGM, including notices of meetings and agendas.
2024-04-29 English
PROPOSED RE-ELECTION OF RETIRING DIRECTORS, PROPOSED GRANTING OF GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES, PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a circular from the Board of Immunotech Biopharm Ltd to its shareholders. It includes detailed information about the proposed re-election of retiring directors, granting of general mandates to issue and repurchase shares, proposed amendments to the memorandum and articles of association, and notice of the Annual General Meeting (AGM). It contains a proxy form and detailed appendices related to these proposals. The document is not a financial report, earnings release, or audit report, but rather a communication to shareholders about matters to be voted on at the AGM. This fits the definition of Proxy Solicitation & Information Statement (PSI), which are materials sent to shareholders to provide information and request votes for meetings. The length and detail confirm it is the actual solicitation document, not just a brief announcement or notice. Therefore, the correct classification is PSI with high confidence.
2024-04-29 English
2023 ANNUAL REPORT
Annual Report Classification · 100% confidence The document is titled '2023 ANNUAL REPORT' and contains detailed sections typical of an annual report, including Corporate Information, Business and Financial Highlights, Management Discussion and Analysis, Directors and Senior Management, Corporate Governance Report, Financial Summary, Environmental, Social and Governance Report, Independent Auditor’s Report, and detailed consolidated financial statements with notes. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The content includes comprehensive financial and business information for the fiscal year 2023, consistent with an official yearly report covering company activity and full financial performance. Therefore, this document fits the definition of an Annual Report (10-K).
2024-04-29 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2024
Major Shareholding Notification Classification · 95% confidence The document is a detailed monthly return on movements in securities for Immunotech Biopharm Ltd, including authorized share capital, issued shares, share options, convertibles, and confirmations related to securities issued. It is addressed to the Hong Kong Exchanges and Clearing Limited and references compliance with listing rules. The content focuses on share capital changes and securities movements rather than financial performance, earnings, or management commentary. It is not an annual or interim report, earnings release, or management discussion. It is a regulatory submission related to share capital and securities movements under exchange listing rules. This type of document fits best under 'Major Shareholding Notification' (MRQ) as it reports on share capital and securities movements, which is consistent with notifications of significant share ownership or capital structure changes. The document length and detail confirm it is not a brief announcement but a substantive regulatory filing on share capital movements.
2024-04-03 English
PROPOSED AMENDMENTS TO THE EXISTING MEMORANDUM AND ARTICLES OF ASSOCIATION AND ADOPTION OF THE FOURTH MEMORANDUM AND ARTICLES OF ASSOCIATION
Regulatory Filings Classification · 95% confidence The document is an announcement from Immunotech Biopharm Ltd regarding proposed amendments to the company's memorandum and articles of association and the adoption of a new version of these documents. It mentions that these changes are subject to shareholder approval at the forthcoming AGM and that a circular with detailed information and a notice of the AGM will be sent to shareholders. The document is relatively short (2664 characters) and serves as a notification about proposed governance changes and the upcoming AGM, rather than the AGM materials themselves or the actual amended documents. It does not contain financial data, audit information, or detailed management discussion. It is not a report but an announcement related to governance changes and the AGM process. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2024-03-28 English
ANNOUNCEMENT OF ANNUAL RESULTS FOR THE YEAR ENDED 31 DECEMBER 2023
Annual Report Classification · 95% confidence The document is an announcement of annual results for the year ended 31 December 2023 by Immunotech Biopharm Ltd. It contains detailed financial highlights, business highlights, clinical trial updates, and management discussion and analysis. The content includes audited consolidated results and comparative figures, which are typical of a comprehensive annual financial report. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the full annual report rather than a brief announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2024-03-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.